Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.

BMC urology - 28 Jan 2013

Olsson Hans, Hultman Per, Rosell Johan, Söderkvist Peter, Jahnson Staffan

Abstract excerpt

BACKGROUND: Urinary bladder carcinoma stage T1 is an unpredictable disease that in some cases has a good prognosis with only local or no recurrence, but in others can appear as a more aggressive tumor with progression to more advanced stages. The aim here was to investigate stage T1 tumors regarding MDM2 promoter SNP309 polymorphism, mutations in the p53 gene, and expression of p53 and p16 measured by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Transitional Cell
Share to Cyclin-Dependent Kinase Inhibitor p16

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Kaplan-Meier Estimate

Share to Proportional Hazards Models

Share to Proto-Oncogene Proteins c-mdm2

Share to Retinoblastoma Protein

Share to Urinary Bladder Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 23356517
DOI: 10.1186/1471-2490-13-5
PMCID: PMC3574032

Genes

MDM2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MDM2 SNP309 promoter polymorphism and p53 mutations in urinary bladder carcinoma stage T1.PMID 23356517Read ↗

Mdm2 SNP309 G-variant is associated with invasive growth of human urinary bladder cancer.Semantic proximity Read ↗

The p53 Pathway and Outcome among Patients with T1G3 Bladder TumorsSemantic proximity Read ↗

A polymorphism in HDM2 (SNP309) associates with early onset in superficial tumors, TP53 mutations, and poor outcome in invasive bladder cancer.Semantic proximity Read ↗

Prognostic implications of p53 gene mutations in bladder tumors.Semantic proximity Read ↗

The MDM2 SNP309T>G polymorphism increases bladder cancer risk among Caucasians: a meta-analysis.Semantic proximity Read ↗

Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes.Semantic proximity Read ↗

Clinical implications of the MDM2 SNP309 and p53 Arg72Pro polymorphisms in transitional cell carcinoma of the bladder.Semantic proximity Read ↗

Prognostic value of molecular markers, sub-stage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer.Semantic proximity Read ↗

Human papilloma virus DNA and p53 mutation analysis on bladder washes in relation to clinical outcome of bladder cancer.Semantic proximity Read ↗

Association of TP53 and MDM2 polymorphisms with survival in bladder cancer patients treated with chemoradiotherapy.Semantic proximity Read ↗

Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers.Semantic proximity Read ↗

Insertion/deletion polymorphism in the promoter of NFKB1 as a potential molecular marker for the risk of recurrence in superficial bladder cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.